Lord Markham: ...to generate antibodies following vaccination and 40% mounted a low serological response. The National Institute for Health and Care Excellence (NICE) is conducting a Health Technology Evaluation of Evusheld, which will provide guidance on the use of Evusheld within the NHS. Part of this evaluation will include consideration of the cohorts that could benefit if NICE recommends its use as a...
Will Quince: ...treatments have been deemed unsuitable. The National Institute for Health Excellence (NICE) is currently evaluating the treatments for COVID-19, including existing antiviral treatments, as well as Evusheld as a prophylactic. If NICE finds the medicines clinically and cost effective, the National Health Service will make them available as appropriate. We are also exploring options for an...
Tim Loughton: ...for Health and Social Care, with reference to the correspondence from the hon. Member for East Worthing and Shoreham of 6 September 2022 and 1 November 2022, for what reason (a) he will not meet Evusheld campaigners and (b) his correspondence of 15 December 2022 did not refer to the request for a meeting.
Ben Bradshaw: To ask the Secretary of State for Health and Social Care, what criteria his Department uses to assess the cost-effectiveness of the use of Evusheld against the cost of admission to a hospital for an immune-compromised person with complex health conditions.
the Bishop of Exeter: To ask His Majesty's Government what assessment they have made of the cost effectiveness of Evusheld in the treatment of immuno-compromised persons with complex health needs against the cost of an admission to hospital, given the increase in COVID-19 hospital admissions and the pressure on the NHS.
Mark Pritchard: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of NICE bringing forward proposals to support the introduction of next generation of Evusheld to offer protection against covid-19 for those people for whom traditional covid-19 vaccines offer limited or no protection.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, if he will publish a list of all available world-wide source material on the effectiveness of Evusheld and within that list, to identify which source material, if any, were excluded by Rapid C-19 when producing advice on Evusheld procurement to Ministers, and on what criterion.
Lord Mendelsohn: To ask His Majesty's Government whether they will ensure that immunocompromised patients will have to wait no more than nine months from approval to get the prophylactic antibodies Evusheld.
Thangam Debbonaire: To ask the Secretary of State for Health and Social Care, with reference to the Government's decision on Evusheld, what steps he is taking to help protect those people acutely vulnerable to covid-19.
Lord Mendelsohn: ...Majesty's Government what papers and data were consulted in advance of the Secretary of State for Health and Social Care and Chief Medical Officer taking the decision not to pursue procurement of Evusheld; and what is the most recent real time evidence of Evusheld’s effectiveness that they have consulted.
Lord Mendelsohn: ...Majesty's Government what plans they have to undertake an equalities assessment on the availability of protection from COVID-19, given that immunocompromised and vulnerable patients' only access to Evusheld costs up to £3,000 on the private market.
Lord Markham: ...expertise in the therapeutic options available and consults experts in an NHS expert working group and the Prophylaxis Oversight Group. The Chief Medical Officer for England has agreed that Evusheld should be referred to the National Institute for Health and Care Excellence for further evaluation, which is underway
Baroness Whitaker: To ask His Majesty's Government what assessment they have made of the number of immunocompromised people in England who could potentially benefit from Evusheld if it is found to be appropriate for prescription on the NHS.
Baroness Whitaker: To ask His Majesty's Government why, given that Evusheld has been approved for private prescription, it has not yet been approved for prescription on the NHS.
Baroness Whitaker: To ask His Majesty's Government when they expect a decision to be made as to the suitability of prescribing Evusheld on the NHS.
Lord Mendelsohn: To ask His Majesty's Government whether a recommendation by Rapid C-19 is stopping the provision of Evusheld in the NHS by Christmas.
Lord Mendelsohn: To ask His Majesty's Government whether Evusheld will be available to NHS patients before Christmas.
Lord Mendelsohn: To ask His Majesty's Government whether they will rule out the possibility that patients will receive a placebo in place of Evusheld.
Lord Mendelsohn: To ask His Majesty's Government what discussions they have had with experts in any of the 32 countries using Evusheld on their real time testing and trials.
Lord Mendelsohn: To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, how many members of the RAPID C-19 Oversight Group were (1) full time clinicians or doctors, and (2) clinicians who treat immunocompromised patients.